Cypress Asset Management Inc. TX Invests $1.53 Million in Thermo Fisher Scientific Inc. (NYSE:TMO)

Cypress Asset Management Inc. TX bought a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 2,897 shares of the medical research company's stock, valued at approximately $1,532,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Cypress Advisory Group LLC purchased a new stake in Thermo Fisher Scientific in the fourth quarter worth $253,000. Intact Investment Management Inc. grew its stake in shares of Thermo Fisher Scientific by 34.0% in the fourth quarter. Intact Investment Management Inc. now owns 2,600 shares of the medical research company's stock worth $1,353,000 after acquiring an additional 660 shares during the last quarter. Purkiss Capital Advisors LLC purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth $1,121,000. Fifth Third Bancorp grew its stake in shares of Thermo Fisher Scientific by 11.6% in the fourth quarter. Fifth Third Bancorp now owns 335,053 shares of the medical research company's stock worth $174,305,000 after acquiring an additional 34,917 shares during the last quarter. Finally, Independence Bank of Kentucky grew its stake in shares of Thermo Fisher Scientific by 21.0% in the fourth quarter. Independence Bank of Kentucky now owns 3,825 shares of the medical research company's stock worth $1,990,000 after acquiring an additional 663 shares during the last quarter. Institutional investors own 89.23% of the company's stock.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 3,775 shares of the company's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $532.52, for a total value of $2,010,263.00. Following the completion of the sale, the senior vice president now directly owns 10,816 shares in the company, valued at approximately $5,759,736.32. This represents a 25.87% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of the company's stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the sale, the executive vice president now owns 23,167 shares of the company's stock, valued at $9,960,188.31. This represents a 1.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 14,075 shares of company stock worth $7,305,942. 0.33% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research firms have recently commented on TMO. Stifel Nicolaus cut their target price on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a research note on Thursday, April 24th. Morgan Stanley upped their price target on Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an "overweight" rating in a report on Friday, January 31st. The Goldman Sachs Group set a $610.00 price target on Thermo Fisher Scientific and gave the company a "buy" rating in a report on Wednesday, April 23rd. Wells Fargo & Company lowered their price target on Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating on the stock in a report on Thursday, April 24th. Finally, Argus lowered their target price on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating on the stock in a report on Tuesday, April 29th. Four analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Thermo Fisher Scientific currently has an average rating of "Moderate Buy" and an average price target of $607.43.

Thermo Fisher Scientific Price Performance

TMO traded down $1.67 on Wednesday, hitting $401.88. 1,930,021 shares of the company's stock traded hands, compared to its average volume of 1,874,739. The company's 50 day simple moving average is $437.74 and its 200-day simple moving average is $502.70. The firm has a market cap of $151.71 billion, a price-to-earnings ratio of 24.31, a P/E/G ratio of 2.99 and a beta of 0.82. Thermo Fisher Scientific Inc. has a one year low of $390.50 and a one year high of $627.88. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $5.10 by $0.05. The business had revenue of $10.36 billion during the quarter, compared to analysts' expectations of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The firm's revenue for the quarter was up .2% compared to the same quarter last year. During the same quarter last year, the business posted $5.11 EPS. As a group, research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.43%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.09%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.